Investigational Drug Details
| Drug ID: | D006 |
| Drug Name: | Phenylalanine |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB00120 |
| DrugBank Description: | Phenylalanine is an essential aromatic amino acid that is a precursor of melanin, [dopamine], [noradrenalin] (norepinephrine), and [thyroxine]. |
| PubChem ID: | 6140 |
| CasNo: | 63-91-2 |
| Repositioning for NAFLD: | Yes |
| SMILES: | N[C@@H](CC1=CC=CC=C1)C(O)=O |
| Structure: |
|
| InChiKey: | COLNVLDHVKWLRT-QMMMGPOBSA-N |
| Molecular Weight: | 165.1891 |
| DrugBank Targets: | Tyrosine aminotransferase; Large neutral amino acids transporter small subunit 2; Phenylalanine--tRNA ligase alpha subunit; Phenylalanine-4-hydroxylase; Phenylalanine--tRNA ligase, mitochondrial; Phenylalanine--tRNA ligase beta subunit; Tyrosine 3-monooxygenase |
| DrugBank MoA: | The supposed antidepressant effects of L-phenylalanine may be due to its role as a precursor in the synthesis of the neurotransmitters norepinephrine and dopamine. Elevated brain norepinephrine and dopamine levels are thought to be associated with antidepressant effects. <br/>The mechanism of L-phenylalanine's possible antivitiligo activity is not well understood. It is thought that L-phenylalanine may stimulate the production of melanin in the affected skin |
| DrugBank Pharmacology: | Used by the brain to produce Norepinephrine, a chemical that transmits signals between nerve cells and the brain; keeps you awake and alert; reduces hunger pains; functions as an antidepressant and helps improve memory. |
| DrugBank Indication: | L-phenylalanine may be helpful in some with depression. It may also be useful in the treatment of vitiligo. There is some evidence that L-phenylalanine may exacerbate tardive dyskinesia in some schizophrenic patients and in some who have used neuroleptic drugs. |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L1315 | NCT05944016 | PHASE3 | RECRUITING | NO | 2024-03-25 | 2024-12-16 | Details |
| L2072 | NCT02147431 | PHASE1 | COMPLETED | NO | 2014-05-21 | 2018-08-13 | Details |
| L4429 | NCT01495013 | PHASE3 | COMPLETED | NO | 2011-12 | 2016-11-21 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|